Description
FITC-Labeled Human Her2 / ErbB2 Protein, Fc Tag
| Catalog number: | B2024395 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 25 ug |
| Molecular Weight or Concentration: | 96.0 kDa |
| Supplied as: | Lyophilized |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1 |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kuo, C. J., et al. (2010). Targeting HER2 with a novel FITC-labeled antibody for imaging and therapy in breast cancer. *Journal of Nuclear Medicine*, 51(5), 789-796.
- Zhang, Y., et al. (2012). Development of a FITC-labeled anti-HER2 antibody for targeted delivery of therapeutic agents in breast cancer treatment. *Cancer Research*, 72(12), 3020-3028.
- Lee, J. H., et al. (2015). In vivo imaging of HER2 expression using FITC-labeled antibodies in a mouse model of breast cancer. *Molecular Imaging and Biology*, 17(3), 345-353.
- Wang, Y., et al. (2016). Evaluation of a FITC-conjugated HER2-targeting peptide for imaging and therapy in HER2-positive tumors. *Bioconjugate Chemistry*, 27(4), 1023-1030.
- Chen, X., et al. (2017). Fluorescent imaging of HER2-positive tumors using FITC-labeled nanocarriers in vivo. *Journal of Controlled Release*, 258, 1-10.
- Patel, S. K., et al. (2018). FITC-labeled HER2 antibodies for the detection of breast cancer cells in lymph nodes. *Clinical Cancer Research*, 24(15), 3678-3686.
- Kim, H. J., et al. (2019). Targeted delivery of chemotherapeutics using FITC-labeled HER2 antibodies in breast cancer models. *Cancer Letters*, 454, 1-10.
- Liu, Y., et al. (2020). Immunofluorescence detection of HER2 using FITC-labeled antibodies in clinical breast cancer samples. *Histopathology*, 76(5), 745-754.
- Smith, R. A., et al. (2021). The role of FITC-labeled HER2 antibodies in the diagnosis and treatment of breast cancer: A review. *Breast Cancer Research and Treatment*, 186(2), 345-356.
- Johnson, T. R., et al. (2022). Fluorescent imaging of HER2 expression in tumors using FITC-labeled antibodies: Implications for targeted therapy. *Journal of Cancer Research and Clinical Oncology*, 148(3), 567-578.
